Open Access<p>A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients</p>
Author(s) -
Yang Mi,
Xiufeng Liu,
Cheng Zhang,
Feng Liao,
Zixiong Li,
XueGang Luo,
Y R Sun,
Chao Chen
Publication year - 2019
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s223372
Subject(s) - apatinib , medicine , leukopenia , chemotherapy , mucositis , ovarian cancer , adverse effect , oncology , cancer , progression free survival , gastroenterology , surgery
Despite recent advances in the treatment of advanced ovarian cancer, drug selection after second-line chemotherapy has not been well studied. In this study, we retrospectively evaluated the effect and safety of apatinib as monotherapy or in combination with chemotherapy for the treatment of advanced ovarian cancer after second-line treatment.